Clinical data of CU-201, CUDC-101 presented at EORTC-NCI-AACR Symposium
 

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the presentation of data in two poster presentations at the 22nd EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics," held in Berlin, Germany, November 16-19.

More...